Mod­er­na says it's reached the re­quired num­ber of Covid-19 cas­es for its first in­ter­im analy­sis. When is the read­out com­ing?

Pfiz­er and BioN­Tech came out with the first Phase III in­ter­im analy­sis of their Covid-19 vac­cine ear­li­er this week, and it ap­pears Mod­er­na is right on their heels.

The Cam­bridge, MA-based biotech an­nounced Wednes­day af­ter­noon that it has reached the thresh­old re­quired to con­duct its own ini­tial Phase III in­ter­im analy­sis. And as a re­sult of a “sig­nif­i­cant in­crease” in tri­al par­tic­i­pants con­tract­ing con­firmed cas­es of Covid-19, Mod­er­na al­so ex­pects the analy­sis will in­clude “sub­stan­tial­ly more” than the 53 cas­es orig­i­nal­ly set out for the analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER